Skip to content

Clinical trial for the evaluation of the efficacy and safety of DuolacProAP 4 on the reduction of blood acetaldehyde and alcohol after alcohol consumption

A 12-week, randomized, double-blind, placebo-controlled, cross-over design Clinical trial for the evaluation of the efficacy and safety of DuolacProAP 4 on the reduction of blood acetaldehyde and alcohol after alcohol consumption

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0005361
Enrollment
54
Registered
2020-09-01
Start date
2019-04-01
Completion date
Unknown
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : * Experimental Products(DuolacProAP4) • Main Component: probiotics 4 kinds • intake amount: 1,600 mg/day • Number of intakes and intake period: Intake for 15 day, 2 capsule/day, t

Sponsors

Cell Biotech
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Adult male over the age of 19 and under 65 at the time of the screening test 2) Those who have experienced hangover after drinking 3) Those with a body mass index (BMI) of 18 to 25 kg / m2 4) After hearing the detailed explanation of this human application test and fully understanding it, the person who voluntarily decides to participate and agrees in writing to observe the precautions

Exclusion criteria

Exclusion criteria: 1) ALDH2 genotype homozygote type (ALDH2 * 2 / * 2) 2) A person who has a clinically significant hypersensitivity reaction or has a history of drugs, alcohol, human application test products, or ingredients. 3) A person who has taken drugs that induce and inhibit drug metabolism, such as barbital drugs, within 1 month from the screening test date 4) Drugs that are expected to affect clinical results such as alcohol metabolism within one month from the screening test date (drugs such as aspirin, drugs that have a risk of gastrointestinal bleeding, antipyretic analgesics, anti-inflammatory drugs, antibiotics, herbal medicines, oral steroids, hormones, etc. ) 5) Those who have taken drugs, products and functional foods that are thought to affect the intestines, such as probiotics, lactic acid bacteria-containing beverages (e.g. yogurt), dairy products (e.g. cheese) within one month from the screening test date. 6) Those who have taken drugs, products, and health functional foods that are thought to affect the stomach and liver, such as milk thistle (silimarin) and licorice extract, within one month from the screening test date. 7) Those who have taken other drugs, products, and health functional foods that are considered unsuitable for participation in research by other test takers, such as other hangover-relieving products 8) A person who drinks excessively within one week from the screening test date. 9) Severe acute or chronic cardiovascular disease, metabolic disease, liver and biliary system disease, pancreatic disease, muscle disease, neurological disease, mental disease, endocrine system disease, immune disease, kidney disease, malignant tumor, lung requiring treatment People with diseases and other diseases 10) Patients with clinically significant gastrointestinal diseases such as gastric ulcer and duodenal ulcer or being treated 11) Persons with a history of gastrointestinal disorders (eg Crohn's disease) or gastrointestinal surgery (except simple appendectomy or hernia surgery) that may affect the absorption of human application test products. 12) Those who have had antipsychotic medication within 2 months from the screening test date 13) People with or have a history of alcoholism or substance abuse 14) Those who participated in other human application tests and clinical trials within 3 months from the screening test date (except in the case where there was no in-house administration of drugs or food (injection, intake, insertion, etc.) as a simple observational study) 15) Those who donated whole blood within 2 months from the screening test date, or who donated components within 2 weeks 16) A person who shows the following results in a diagnostic test ? AST, ALT> 2 times the upper limit of the reference range ? Serum creatinine> 2.0 mg / dl ?Creatine kinase> 2 times the upper limit of the reference range 17) A person who is determined by the test manager to be unsuitable for participation in the study due to other reasons, including the results of diagnostic tests and medical tests

Design outcomes

Primary

MeasureTime frame
Acetaldehyde in the blood after alcohol consumption;Blood alcohol after alcohol consumption

Secondary

MeasureTime frame
Scores for symptoms of hangover after alcohol consumption;Liver function indicators;Blood sugar index

Countries

Korea, Republic of

Contacts

Public Contactji Hwang

Chonbuk National University Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026